We identified 340 pediatric patients (65.3% male, average age 11.9 years) who had been prescribed a VMAT2 inhibitor for a variety of hyperkinetic movement disorders (359 total prescriptions) at our large pediatric movement disorders center. This evidence concerns the gene SLC18A2 and movement disorder.